USSTOCK.TODAY
Market Closed
Log in Sign up

Beam Therapeutics Announces Topline Data from Phase 1/2 Clinical Trial of Sickle Cell Disease Cell Therapy

Clinical Trials Arena +1 · ·by G4L

BEAM
BEAM Beam Therapeutics Inc
$25.15 -6.92%
View chart & analysis →
  1. 1Beam Therapeutics announced topline data from its Phase 1/2 clinical trial of a cell therapy for sickle cell disease.
  2. 2As of October 20 data, 39 adult patients and 10 adolescent patients were treated in the Beam Therapeutics BEACON clinical trial.
  3. 3Beam Therapeutics plans to submit a Biologics License Application (BLA) for risto-cel to the US FDA by the end of 2026.

So what's the key point?

Beam Therapeutics has released clinical trial results for its sickle cell disease treatment. The company plans to apply for regulatory approval to sell the drug in the US by the end of 2026.

Source Clinical Trials Arena +1 · View original ↗

Related 3-line summaries

Cathie Wood continues buying Beam Therapeutics (BEAM) The Motley Fool +1 · Oct 18Power Generation Companies Expand to Meet AI Data Center Demand The Motley Fool +1 · 35m agoNvidia shares fall as investigation into CEO Jensen Huang expands The Motley Fool +1 · 35m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news